Qualigen Therapeutics Inc (QLGN) Stock Price, Quote & News

Company Profile

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced s...

Industry: Biotechnology

Sector: Healthcare

Phone: 760 452 8111

Website: www.qlgntx.com

Address:

5857 Owens Avenue, Suite 300, Carlsbad, United States

Sanesh Jun. 11 at 8:06 PM

$JAGX shorty spooked it didn't make new low $FOXO $SUNE $DKNG $QLGN

0 · Reply

BigShizzle54 Jun. 9 at 8:48 PM

$QLGN next up is >>>> 🔥 $$CARM

0 · Reply

Mistaworldwide305 Jun. 7 at 2:48 PM

$QLGN two things... 1) glad to see there are 0 bulls here... 2) how is this not delisted?

0 · Reply

WallStreetPro2021 Jun. 3 at 9:36 PM

$HD $L $ENPH $KO $QLGN Piper Sandler issues a $11.00 price target on PROP – Prairie Operating, trading at $3.98 a share. Upstream producer Prairie Operating Company (PROP), lots of insider buys in the last two weeks as their acquisition on Bayswater completed and significant production was added. They are well hedged at $68.27 a barrel for 2025 and from Q1 2026 thru Q1 2028 at $64.29 a barrel. Piper Sandler issues a $11.00 price target, trading at $3.98 a share. https://www.investing.com/news/analyst-ratings/piper-sandler-sets-11-target-for-prairie-operating-stock-93CH-4011820 Actual Piper Sandler 31- page analysis attached https://storage.googleapis.com/vendorgroup-assets/site/4308a1c5-ae18-4626-847f-4861aa44b367/2025/04/30/681255b42f7fb57b7c7e7cd2/Piper-Sandler-4.30.25.pdf

0 · Reply